Suzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.
Suzanne Trudel, MSc, MD
Advertisement
Articles by Suzanne Trudel, MSc, MD
Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple MyelomaPublished: August 15th 2024 | Updated:
Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple MyelomaPublished: June 16th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5